YOLFTbeta
Icares Medicus Inc

Icares Medicus Inc

6612 · TWO · Healthcare / Medical Instruments & Supplies

60.40TWD-3.30 (-5.18%)

Price History

Full chart

Market Stats

Previous Close63.70
Open63.80
Day Range60.00 – 63.80
52-Week Range65.11 – 96.20
Volume140.77K
Market Cap3.97B
P/E (TTM)42.50
Forward P/E0.00
EPS1.80
Dividend Yield0.40%
Beta0.29
50-Day Avg68.90
200-Day Avg66.25

About

ICARES Medicus, Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of ophthalmic medical devices in Taiwan, the United States, United Kingdom, Japan, Spain, China, Germany, and internationally. The company is also involved in the manufacturing, sales, and service of intraocular lenses (IOLs) and its implantation systems for use in treating cataracts, myopia, farsightedness, presbyopia, or astigmatism, as well as related technical services. In addition, it offers artificial crystal products; and lubricious implantable and invasive high-end nanomedicine material. Further, the company engages in molding, mold design, and development; production of medical devices and electronic plastic products; and distribution of ophthalmic medical equipment. ICARES Medicus, Inc. was incorporated in 2011 and is based in Zhubei, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryMedical Instruments & Supplies
  • CEOBing Chun Chen
  • Employees0
  • HeadquartersNo. 16, Shengyi Road, Zhubei, Taiwan, Taiwan
  • Websitehttps://www.icaresmedicus.com

Leadership

  • Bing Chun ChenGeneral Manager
  • Ms. Tan-Li ChenVP and Head of Finance & Accounting Department
  • Junming LinVice President of R&D and Operations
  • Mr. Wen-Chu TsengChief R&D Officer & Director
  • Mr. Carl Robert CummingsPresident of Major Subsidiary
  • Mr. Ying-Zong YanDirector

Financials

Income Statement

Currency: TWD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue266.05M329.28M419.36M362.67M393.92M511.85M605.45M859.79M1.13B
Growth (%)-+23.77%+27.36%-13.52%+8.62%+29.94%+18.29%+42.01%+31.54%
Cost of Revenue61.42M94.66M87.53M70.80M71.04M94.41M123.05M260.06M462.81M
Gross Profit204.63M234.63M331.84M291.87M322.88M417.44M482.40M599.73M668.18M
Gross Margin76.91%71.25%79.13%80.48%81.97%81.56%79.68%69.75%59.08%
Operating Expense141.09M145.82M213.74M218.34M245.71M271.33M351.86M470.67M539.75M
Operating Income63.54M88.81M118.10M73.53M77.18M146.11M130.54M129.06M128.42M
Operating Margin23.88%26.97%28.16%20.27%19.59%28.55%21.56%15.01%11.35%
EBITDA82.32M111.42M141.32M103.58M105.87M174.42M174.27M271.78M241.67M
EBITDA Margin30.94%33.84%33.70%28.56%26.88%34.08%28.78%31.61%21.37%
Net Income31.25M70.45M81.02M51.91M58.60M128.91M97.73M103.12M51.23M
Net Income Margin11.74%21.40%19.32%14.31%14.88%25.19%16.14%11.99%4.53%
R&D39.85M41.24M91.16M98.25M104.87M133.08M177.45M192.70M158.94M
R&D as % of Total Revenue14.98%12.52%21.74%27.09%26.62%26.00%29.31%22.41%14.05%
Interest Expense0201.00K1.17M976.00K829.00K576.00K7.17M18.33M24.19M
Interest Expense % of Total Revenue0.00%0.06%0.28%0.27%0.21%0.11%1.18%2.13%2.14%

Balance Sheet

Currency: TWD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets401.48M617.38M792.06M848.05M965.87M1.04B1.91B3.01B3.18B
Total Liabilities64.91M45.96M139.02M145.62M144.96M105.65M239.80M1.25B1.21B
Total Equity335.68M570.08M623.49M665.84M746.78M878.75M1.58B1.66B1.83B
Cash218.80M399.01M310.45M281.34M356.26M284.59M381.26M439.79M459.09M
Total Debt---23.30M17.51M6.16M121.64M--
Net Debt----258.05M-338.74M-278.43M-259.63M271.97M262.26M

Cash Flow

Currency: TWD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow45.47M63.22M88.78M71.37M38.57M128.92M-25.79M-48.52M-58.83M
Investing Cash Flow-22.51M8.51M-161.93M-99.36M-6.60M-202.56M---
Financing Cash Flow-50.47M107.42M-7.70M5.69M46.57M-23.89M656.10M--
Capital Expenditure8.44M6.08M93.41M11.20M6.48M34.03M76.47M156.72M53.47M
Free Cash Flow36.75M54.60M-5.62M60.17M32.09M94.88M-102.26M-205.24M-112.31M
Dividends Paid15.14M15.14M16.76M16.87M3.40M16.98M34.16M7.83M12.92M
FCF to OCF80.81%86.36%-6.33%84.31%83.21%73.60%396.56%422.99%190.89%
Dividend Paid to FCF41.20%27.73%-298.38%28.03%10.59%17.90%-33.41%-3.82%-11.51%

Earnings

Report DateMar 31, 2017Jun 30, 2017Sep 30, 2017Mar 27, 2018May 14, 2018Aug 12, 2018Nov 26, 2018Mar 25, 2019May 13, 2019Aug 11, 2019Nov 7, 2019Mar 15, 2020May 7, 2020Aug 5, 2020Nov 6, 2020Mar 16, 2021May 13, 2021Aug 11, 2021Nov 11, 2021Mar 16, 2022May 11, 2022Aug 9, 2022Nov 10, 2022Mar 9, 2023May 11, 2023
EPS Estimate-----0.720.710.520.600.690.550.59-0.390.52-0.530.440.54------
EPS Actual0.120.360.72-0.170.441.040.540.220.170.660.580.410.700.150.50-0.020.140.190.390.770.880.801.430.690.77
Surprise-----44.44%-23.94%-57.69%-71.67%-4.35%5.45%-30.51%--61.54%-3.85%--73.58%-56.82%-27.78%------
Timing---After-hoursPre-marketAfter-hoursPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketAfter-hours

Key Statistics & Ratios

Market Cap3.97B
Enterprise Value3.75B
Trailing P/E42.50
Forward P/E0.00
Price / Sales3.28
Price / Book1.96
EPS1.80
Book Value36.51
Revenue (TTM)1.21B
Gross Profit (TTM)683.39M
EBITDA234.53M
Profit Margin7.73%
Operating Margin10.33%
Return on Equity1.63%
Return on Assets2.38%
Shares Outstanding51.90M
Shares Float25.57M
Beta0.29
Dividend Yield0.40%
Dividend Rate0.30
Payout Ratio15.15%

Dividends

20261×
0.30Aug 26, 2026
20251×
0.27Aug 22, 2025
20241×
0.17Jul 8, 2024
20231×
0.74Mar 30, 2023
20221×
0.37Apr 7, 2022
20211×
0.07Jul 16, 2021
20201×
0.37Jun 19, 2020
20191×
0.37Jul 17, 2019
20181×
0.37Jun 21, 2018

Stock Splits

  • Aug 26, 20261100.7699:1000
  • Aug 22, 20251100:1000
  • Jul 8, 20241100:1000